Arcturus Up 26% After Hours on CSL Seqirus Vaccine Collaboration

By Josh Beckerman

Arcturus Therapeutics Holdings Inc. shares rose 26% to $23.10 after hours as the company announced a vaccine collaboration with CSL Ltd.'s CSL Seqirus.

Arcturus will receive $200 million upfront and is eligible to receive over $1.3 billion in development milestones and more than $3 billion in commercial milestones.

In addition, it is eligible to receive a 40% net profit share for Covid-19 vaccine products and up to double-digit royalties for certain other vaccines.

Write to Josh Beckerman at [e-mail]

(END) Dow Jones Newswires

11-01-22 1912ET